Skip to main content
. 2021 Oct 19;12:762548. doi: 10.3389/fendo.2021.762548

Table 3.

Differences in clinical characteristics between pheochromocytoma patients with and without recurrence.

Patients Total patients Recurrence group No recurrence group P value
Male 43% (63/146) 39% (26/67) 47% (37/79) 0.329
Age at diagnosis, y 36 ± 15.0 32.8 ± 15.3 39.4 ± 13.3 0.007
Follow-up time, y 7.0 (5.0,9.0) 6.0 (4.0,9.0) 8.0 (7.0,9.0) 0.000
Primary tumor size 5.8 ± 2.4 6.3 ± 2.3 5.5 ± 2.5 0.048
Tumor size≥5cm 64% (86/135) 75% (50/67) 46% (36/79) 0.000
Gene mutation 33% (42/126) 39% (21/53) 29% (21/73) 0.067
SDHB 6% (8/126) 9% (5/53) 4% (3/73) 0.226
VHL 8% (10/126) 13% (7/53) 4% (3/73) 0.062
RET 13% (19/126) 11% (6/53) 18% (13/73) 0.315
MAX 2% (2/126) 4% (2/53) 0% (0/73) 0.090
Tumor site
Left adrenal gland 41% (59/146) 45% (29/67) 38% (30/79) 0.515
Right adrenal gland 40% (60/146) 40% (27/67) 41% (32/79) 0.857
Bilateral adrenal glands 16% (23/146) 15% (10/67) 16% (13/79) 0.800
Multiple primary tumors 18% (27/146) 16% (11/67) 20% (16/79) 0.552
Laparotomy 25% (34/136) 40% (24/60) 13% (10/76) 0.000
Capsular invasion 9% (12/130) 15% (8/52) 5% (4/78) 0.064
Vascular tumor embolus 8% (11/130) 12% (6/52) 6% (5/78) 0.303
Ki-67 count 1% (1%,2%)) 2% (1%, 5%) 1% (1%,2%) 0.005
Ki-67 count ≥3% 22% (24/108) 38% (15/39) 13% (9/69) 0.002

Bold values indicate significant P values.